Syngene International Limited

We are hiring! We are conducting Walk-in interviews at Bengaluru on 20th July 2024 (Saturday) for multiple openings in the Discovery Biology group for DMPK (Drug Metabolism & Pharmacokinetics) department. If you wish to be part of a dynamic, high-performing team for bringing new solutions to drug discovery and changing people's lives for the better, please read more. We seek highly motivated, creative, and results-oriented scientists with multiple positions open at Hyderabad, who have relevant experience in invitro drug metabolism assay, and LCMS-based discovery bioanalysis. The candidate should have an excellent understanding of the fundamentals of drug metabolism and pharmacokinetics principles and drug discovery; prior experience in progressing a project from hit identification to lead optimization is a plus. Qualification and Experience: MSc/MTech/M. Pharm/Ph.D. with 2 to 15 years of relevant experience (Freshers are not eligible for the current open roles) Details as below: Req Id: 56074 - Invitro BA Scientist Click 👉 https://lnkd.in/gF8cKzDF Req Id: 56314 – Invitro ADME Lead Click 👉 https://lnkd.in/gQR8xTeM   Req Id: 56220– Invivo PK Click 👉 https://lnkd.in/gpwDXD-m   Job Location: Bangalore and Hyderabad Date & Time for Registration: 20th July 2024, 09:00 AM to 12.30 PM Bengaluru Venue: Syngene International Ltd., Gate No 2, Velankani Tech park, 43, Hosur Rd, Electronic City, Phase 1, Electronic City, Bengaluru, Karnataka – 560100, India Please apply on the above links and write to 👉 abhisek.padhy@syngeneintl.com with the subject line “Syngene DMPK Walk-in Drive” for more details. #Syngene #WalkinDrive #WeareHiring #Hiring #WalkinInterview

📌 Did you know that Green Chemistry is revolutionizing the Biopharma industry? Green chemistry aims to bring in innovative research in developing alternative sustainable technologies that focuses on designing products and processes that minimize or eliminate the use and generation of hazardous substances. At Syngene, our scientists believe that drug discovery and process development are the right stages for applying sustainable ideas which in turn can create manufacturing processes that have minimal environmental impact. Further, applying a Green strategy in drug development can reduce the number of synthetic conversions, shorten the linear synthetic route, and maximize the atom economy. In this viewpoint, we discuss how we support clients in developing pathbreaking therapies that align with the principles of Green Chemistry. It highlights how we are -- ⦿ Reducing the number of process steps across projects wherever possible ⦿ Using class three solvents for process development and manufacturing ⦿ Reducing, Recovering, and Recycling catalysts wherever possible ⦿ Adopting mathematical modeling and simulation at the process research and development level, bringing down the number of experiments ⦿ Ensuring solvent recovery and reuse for the process, wherever applicable To read the full viewpoint, visit the link in the comments below. #greenchemistry #sustainability

📌 Expanding Horizons: Syngene-Cromos Pharma Alliance Transforms Clinical Research 🤝 We're thrilled to announce our strategic alliance with Cromos Pharma!  This partnership combines our expertise in offering high-quality execution and global coverage for clinical trials. Together, we simplify patient recruitment across the Americas, Europe, and India, while providing comprehensive clinical development services. Superior project management ensures seamless execution of global trials and unified project updates.   #ClinicalTrials #StrategicAlliance #Syngene #CromosPharma #DrugDevelopment

📌 #Whitepaper: ADCs as biological missiles for targeted therapies. Antibody-Drug Conjugates (ADCs) continue to show remarkable efficacy across various tumor types. As new technologies emerge and more suitable target antigens are identified, the potential for ADCs expands even further. ADCs target specific proteins on tumor cells, releasing cytotoxic drugs directly into cancer cells, unlike traditional chemotherapy which can harm healthy cells. Syngene offers integrated services for ADCs for discovery, development and manufacturing services, backed by strong conceptual frameworks and cutting-edge technology. Our capabilities range from pharmacokinetics and toxicology to discovery-grade conjugation, linker payload synthesis, and antibody discovery and engineering. Key highlights as follows: • End-to-end discovery platform for ADCs: from antibody engineering to conjugation • Experience with various mAb formats such as bispecifics • Deep expertise in linkers, cytotoxic and non-cytotoxic payloads manufacturing • State-of-the-art analytical capabilities specific to ADCs • cGMP antibody manufacturing with industry leading titres and timelines Read the full whitepaper to explore the market growth of ADCs, innovations in the ADC space, and the future of ADCs as a targeted therapy for various diseases. Link in comments section 🔗

🌟 India's Biopharma Evolution 🌟 India is transforming into a global powerhouse in generic drugs and vaccines, and now it's poised to lead in biopharma too. With a strong biotechnology sector, scientific expertise, and cost-effective manufacturing, India stands at the brink of this exciting expansion. In the latest article, our ED and CFO, Sibaji Biswas, shares insights on the necessity of collaboration to build a sustainable and scalable pharma ecosystem. He highlights the support of government initiatives like PRIP, BIRAC grants, and the PLI scheme in driving this growth. 📄 Dive into the full article to learn more about India's biopharma journey. Link in comments section 🔗 #Biopharma #Pharmaceuticals #Innovation #IndiaPharma #Syngene

🌟 Accelerate Your Drug Discovery🌟   For a molecule to advance from early-stage discovery to successful clinical trials, accurate and reliable preclinical trial data is crucial. This requires robust testing and adherence to regulatory guidelines (FDA/EMA).   Syngene’s safety assessment and toxicology team provides comprehensive exploratory and GLP toxicology studies, supported by clinical and anatomic pathology, formulation analysis, and toxicokinetic analysis. We ensure high-quality reports with secure electronic data transfer and industry-leading turnaround times. For more details, visit the link in comments section 🔗   #Syngene #DrugDevelopment #Toxicology #Pharmaceuticals #PreclinicalTrials

🚀 From Sequence to Vial in 10 Months: Accelerate Your mAb Development with Syngene's Comprehensive CDMO Services!   From cell line development to commercial manufacturing, Syngene offers a comprehensive solution for your monoclonal antibody projects. Our expertise includes: • Proprietary CHO line with >95% clonal stability • High-throughput process development • In-house analytical capabilities • Clinical manufacturing up to 2000L scale   🏆 Key Advantages: • 140+ successful projects • 25+ INDs enabled • 10 months from CLD to clinic • 7-12 g/L titers achieved   Ready to fast-track your mAb to market? Let's connect and explore how Syngene can accelerate your next breakthrough! Link in comments sections 🔗   #Syngene #CDMO #Biopharma #mAbDevelopment #DrugDiscovery

We are hiring! We are conducting walk-in interviews on 13th July 2024 (Saturday) for multiple openings in the Discovery Chemistry Team Walk-in at Bengaluru & Hyderabad Discovery Chemistry – Synthetic & Medicinal Chemistry Qualification & Experience : Medicinal Chemistry – M.Sc. / M Pharm / PhD. With 3+ years’ experience Synthetic Chemistry - M.Sc. / M Pharm / PhD. With 5+ years’ experience Job Location: Bengaluru & Hyderabad Date & Time for Registration : 13th July 2024, 09:00 AM to 12:00 PM Bengaluru Venue : Syngene International Ltd., Gate No.2, Velankani Tech Park, 43, Hosur Rd, Electronics City Phase 1, Electronics City, Bengaluru, Karnataka – 560100. Hyderabad Venue : Syngene Scientific Solution Ltd., Knowledge Square Park -9000, Plot No.7, Survey No.542, MN Park, Synergy Square 2 Genome Valley, Kolthur Shamirpet, Medchal, Hyderabad, Telangana 500078. For any queries please write to 👉 m.malavika@syngeneintl.com/ soniaramesh.more@syngeneintl.com the subject line should be “Syngene Discovery Chemistry Walk-in Drive on 13th July 2024”. #Syngene #Hiring #Jobannouncement #Walkindrive

Adapting to a Changing Biopharmaceutical Landscape! The biopharmaceutical sector is evolving rapidly due to geopolitical tensions and regulatory changes, such as the BIOSECURE Act and the 2032 decoupling deadline from Chinese CDMOs. Chloe Euripides of the International Biopharmaceutical Industry Journal interviewed representatives from top Indian CDMOs to understand their strategies in this new landscape.    Read insights from Alex Del Priore, Syngene’s SVP of Manufacturing, on Syngene’s integrated services, advanced technologies, and strategic collaborations, positioning the company as a formidable global CDMO player amidst the evolving biopharmaceutical landscape. Link in comments 🔗

Are you interested in the latest advancements in cancer research? We invite you to read our new blog post that delves into one of the main challenges in the field: the development of experimental models and how our scientists have developed tumor models that closely mimic the natural environment of the tumor inside the human body. These models are crucial for studying the progress of cancer and testing the response of novel cancer drug candidates before they are administered to humans. Read now, link in comments section. 🔗 #Syngene #BioPharma #tumormodels #